losartan has been researched along with Congenital Limb Deformities in 1 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "Losartan is a promising candidate drug for treatment of GPHYSD due to FBN1 defects." | 1.51 | Skin fibroblasts of patients with geleophysic dysplasia due to FBN1 mutations have lysosomal inclusions and losartan improves their microfibril deposition defect. ( Bacino, CA; Brunetti-Pierri, N; Hicks, J; Mithbaokar, P; Piccolo, P; Polishchuk, E; Polishchuk, R; Sabatino, V, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Piccolo, P | 1 |
| Sabatino, V | 1 |
| Mithbaokar, P | 1 |
| Polishchuk, E | 1 |
| Hicks, J | 1 |
| Polishchuk, R | 1 |
| Bacino, CA | 1 |
| Brunetti-Pierri, N | 1 |
1 other study available for losartan and Congenital Limb Deformities
| Article | Year |
|---|---|
Skin fibroblasts of patients with geleophysic dysplasia due to FBN1 mutations have lysosomal inclusions and losartan improves their microfibril deposition defect.
Topics: Adolescent; Bone Diseases, Developmental; Child; Child, Preschool; Extracellular Matrix; Female; Fib | 2019 |